VCEL Vericel

Vericel Co. (NASDAQ:VCEL) Shares Acquired by GW&K Investment Management LLC

GW&K Investment Management LLC lifted its holdings in shares of Vericel Co. (NASDAQ:VCEL – Get Rating) by 169.9% in the 1st quarter, according to the company in its most recent 13F filing with t

08-09 09:01 ET

H.C. Wainwright Sticks to Its Buy Rating for Vericel (VCEL)

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Vericel (VCEL – Research Report) yesterday and set a price target of $53.00. The company's shares closed last Thursday at $30

08-05 05:20 ET

Vericel (NASDAQ:VCEL) Shares Gap Down to $31.81

Shares of Vericel Co. (NASDAQ:VCEL – Get Rating) gapped down prior to trading on Wednesday . The stock had previously closed at $31.81, but opened at $29.85. Vericel shares last traded at $33.27, wit

08-05 05:01 ET

Vericel Corporation CEO Nick Colangelo on Q2 2022 Results -- Earnings Call Transcript >VCEL

From Seeking Alpha: Vericel Corporation CEO Nick Colangelo on Q2 2022 Results -- Earnings Call Transcript

08-03 03:01 ET

Analysts Conflicted on These Healthcare Names: Vericel (VCEL), Addus Homecare (ADUS) and Baxter International (BAX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vericel (VCEL – Research Report), Addus Homecare (ADUS – Research Report) and Baxter International (B

08-03 12:45 ET

Vericel Q2 Net Loss Widens as Revenue Declines; Full-Year Sales Outlook Maintained

09:32 AM EDT, 08/03/2022 (MT Newswires) -- Vericel (VCEL) reported a Q2 net loss Wednesday of $0.19 per diluted share, widening from a loss of $0.08 a year earlier. Five analysts polled by Capital IQ

08-03 09:32 ET

Vericel: Q2 Earnings Insights

Vericel (NASDAQ:VCEL) reported its Q2 earnings results on Wednesday, August 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Vericel missed estimated earnings b

08-03 08:38 ET

Vericel GAAP EPS of -$0.19 misses by $0.07, revenue of $37.05M misses by $1.3M

Vericel press release (NASDAQ:VCEL): Q2 GAAP EPS of -$0.19 misses by $0.07. Revenue of $37.05M (-6.3% Y/Y) misses by $1.3M. FY2022 Outlook: Total revenue guidance maintained at $178M to $189M vs.

08-03 08:38 ET

MediWound refiling for NexoBrid to treat severe thermal burns gets FDA review

The U.S. Food and Drug Administration (FDA) accepted for review MediWound's (NASDAQ:MDWD) re-submitted biologics license application (BLA) seeking approval of NexoBrid for eschar (dead tissue) removal

08-03 08:25 ET

Vericel 2Q Loss/Shr 19c >VCEL

Vericel 2Q Loss/Shr 19c >VCEL

08-03 07:55 ET